Phathom Pharmaceuticals (PHAT) Non-Current Debt (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Non-Current Debt data on file, last reported at $163.7 million in Q1 2026.

• On a quarterly basis, Non-Current Debt fell 19.47% year-over-year to $163.7 million in Q1 2026; TTM through Mar 2026 was $163.7 million, a 19.47% decrease from a year earlier, with the FY2025 full-year figure at $209.1 million, up 3.81% from the prior year.
• Non-Current Debt for Q1 2026 stood at $163.7 million, down from $209.1 million in the prior quarter.
• Over the last five years, Non-Current Debt for PHAT reached as high as $209.1 million in Q4 2025 and fell as low as $91.0 million in Q1 2022.
• Historically, Non-Current Debt has averaged $146.6 million across 5 years, with a median of $149.0 million in 2024.
• Across the five-year window, Non-Current Debt surged 155.82% in 2022 and decreased 19.47% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $95.3 million in 2022, then soared by 44.69% to $137.8 million in 2023, then surged by 46.12% to $201.4 million in 2024, then advanced by 3.81% to $209.1 million in 2025, then decreased by 21.72% to $163.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $163.7 million in Q1 2026, $209.1 million in Q4 2025, and $207.1 million in Q3 2025.